A competing risks model with binary time varying covariates for estimation of breast cancer risks in BRCA1 families

Mammographic screening and prophylactic surgery such as risk-reducing salpingo oophorectomy can potentially reduce breast cancer risks among mutation carriers of BRCA families. The evaluation of these interventions is usually complicated by the fact that their effects on breast cancer may change over time and by the presence of competing risks. We introduce a correlated competing risks model to model breast and ovarian cancer risks within BRCA1 families that accounts for time-varying covariates. Different parametric forms for the effects of time-varying covariates are proposed for more flexibility and a correlated gamma frailty model is specified to account for the correlated competing events.We also introduce a new ascertainment correction approach that accounts for the selection of families through probands affected with either breast or ovarian cancer, or unaffected. Our simulation studies demonstrate the good performances of our proposed approach in terms of bias and precision of the estimators of model parameters and cause-specific penetrances over different levels of familial correlations. We applied our new approach to 498 BRCA1 mutation carrier families recruited through the Breast Cancer Family Registry. Our results demonstrate the importance of the functional form of the time-varying covariate effect when assessing the role of risk-reducing salpingo oophorectomy on breast cancer. In particular, under the best fitting time-varying covariate model, the overall effect of risk-reducing salpingo oophorectomy on breast cancer risk was statistically significant in women with BRCA1 mutation.

[1]  Jacques Simard,et al.  Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction. , 2020, Biostatistics.

[2]  H. Jacqmin-Gadda,et al.  Joint nested frailty models for clustered recurrent and terminal events: An application to colonoscopy screening visits and colorectal cancer risks in Lynch Syndrome families , 2020, Statistical methods in medical research.

[3]  W. Chung,et al.  Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk , 2018, Journal of the National Cancer Institute.

[4]  J. Horrocks,et al.  Exponential decay for binary time‐varying covariates in Cox models , 2018, Statistics in medicine.

[5]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[6]  W. Chung,et al.  Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers , 2017, Journal of the National Cancer Institute.

[7]  Aung Ko Win,et al.  Modeling of successive cancer risks in Lynch syndrome families in the presence of competing risks using copulas , 2017, Biometrics.

[8]  A. Green,et al.  Gene analysis techniques and susceptibility gene discovery in non-BRCA1/BRCA2 familial breast cancer. , 2015, Surgical oncology.

[9]  M. Pollán,et al.  Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. , 2014, Breast.

[10]  G. Parmigiani,et al.  Calibrated predictions for multivariate competing risks models , 2014, Lifetime data analysis.

[11]  R. Kay The Analysis of Survival Data , 2012 .

[12]  Malka Gorfine,et al.  Frailty‐Based Competing Risks Model for Multivariate Survival Data , 2011, Biometrics.

[13]  G. Feldman,et al.  Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2 , 2010, Genetics in Medicine.

[14]  L. Briollais,et al.  Estimating Disease Risk Associated with Mutated Genes in Family-Based Designs , 2008, Human Heredity.

[15]  M. Gorfine,et al.  On robustness of marginal regression coefficient estimates and hazard functions in multivariate survival analysis of family data when the frailty distribution is mis‐specified , 2007, Statistics in medicine.

[16]  Giovanni Parmigiani,et al.  Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Norman Boyd,et al.  The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer , 2004, Breast Cancer Research.

[18]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical , 2002 .

[19]  Johann Sölkner,et al.  Frailty Models in Survival Analysis , 1996 .

[20]  R Crouchley,et al.  A comparison of frailty models for multivariate survival data. , 1995, Statistics in medicine.

[21]  M. Schumacher,et al.  The impact of heterogeneity on the comparison of survival times. , 1987, Statistics in medicine.

[22]  John D. Kalbfleisch,et al.  Misspecified proportional hazard models , 1986 .

[23]  V T Farewell,et al.  The analysis of failure times in the presence of competing risks. , 1978, Biometrics.

[24]  Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. , 2017, Obstetrics and gynecology.

[25]  A. Yashin,et al.  Genetic analysis of durations: Correlated frailty model applied to survival of Danish twins , 1995, Genetic epidemiology.

[26]  John A. Nelder,et al.  A Simplex Method for Function Minimization , 1965, Comput. J..